Elanco Animal Health Incorporated (ELAN)

NYSE: ELAN · Pharmaceutical Preparations · Indianapolis, IN · filing with the SEC since 2018

Full chart Alerts Compare

Grade6.1

◀ Past 6.8● Present 6.8▶ Future 4.4

Overview Business Financials Grade Forecast Sentiment Ownership People Filings Patents Chart

The companyfiscal 2025, as filed

Revenue$4.71B+6.2%

Net income-$232M-168.6%

Earnings per share$-0.47-169.1%

Operating cash flow$560M+3.5%

Cash$545M+16.5%

Debt$3.76B-12.9%

Shareholders’ equity$6.55B+7.4%

Shares, diluted496.4M+0.5%

Return on equity-3.5%

The recordfrom its filings

Filings in 2026136

Newest filingNov 12 · SCHEDULE 13G/A

Annual reportFeb 24, 2026

Quarterly reportNov 6, 2026

Next report due10-K by Mar 1

Insider sales, 12 months$100,000

Insider buys, 12 months$2.6M

Patents granted67

Filer categoryLarge accelerated filer

Trailing twelve months to Sep 2026Revenue $5.15BNet income -$147MCash from operations $614Mthe four newest filed quarters added

Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.

Revenue and net income by fiscal yearRevenueNet income

16171819202122232425

As filed, in USD. Nothing here is a forecast.

News

Nov 12, 2026 · SEC EDGAR · Form SCHEDULE 13G/A

Large holder update, amended

Open the filing on sec.gov

Nov 6, 2026 · SEC EDGAR · Form 10-Q

Quarterly report

Open the filing on sec.gov

Nov 6, 2026 · SEC EDGAR · Form 8-K

Results released

Open the filing on sec.gov

Nov 5, 2026 · SEC EDGAR · Form SCHEDULE 13G/A

Large holder update, amended

Open the filing on sec.gov

Nov 3, 2026 · SEC EDGAR · Form 3

Insider holding, initial

Open the filing on sec.gov

Nov 3, 2026 · SEC EDGAR · Form 4

Insider trade report

Open the filing on sec.gov

Nov 3, 2026 · SEC EDGAR · Form 4

Insider trade report

Open the filing on sec.gov

Nov 3, 2026 · SEC EDGAR · Form 4

Insider trade report

Open the filing on sec.gov

Oct 20, 2026 · SEC EDGAR · Form 4

Insider trade report

Open the filing on sec.gov

Oct 20, 2026 · SEC EDGAR · Form 4

Insider trade report

Open the filing on sec.gov

An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.

SI brieffrom the record

Core business

Elanco Animal Health Incorporated is classed by the SEC under Pharmaceutical Preparations (industry code 2834), based in Indianapolis, IN. Pet Health was 49% of fiscal 2025 revenue.

Newest on the record

Large holder update, amended on Nov 12. Before it, quarterly report on Nov 6.

What is due next

The 10-K for the period to Dec 31, 2026, due by Mar 1, 2027.

About ELAN

Elanco Animal Health Incorporated is classed by the SEC under Pharmaceutical Preparations (industry code 2834), based in Indianapolis, IN. In its latest annual figures on file, for the fiscal year ended 2025-12-31, it reported revenue of $4.7 billion and a loss of $232 million (its filed statements).

IndustryPharmaceutical Preparations

HeadquartersIndianapolis, IN

Business modelProduct business

ExchangeNYSE

Filing since2018

Fiscal year endsDec 31

SEC number (CIK)1739104

Peers on fileGMAB, OGN, JAZZ, ZTS

Who runs it

Financial performance

In fiscal 2025 Elanco Animal Health’s revenue was $4.71 billion, up 6.2% from $4.44 billion the year before. It made a net loss of $232.0 million.

Annual report, filed Feb 24, 2026.

Financial statements

The grade

Elanco Animal Health grades 6.1 of 10 against its own industry, the 497 companies in Pharmaceutical Preparations. All nine metrics are read as filed.

◀ Past6.8

● Present6.8

▶ Future4.4

How the grade is made

Forecast

Every forecast is registered before the outcome, with the rule that settles it. A miss stays on the page.

Company forecasts

SI Assistanton ELAN · research, not advice